Anne Cooper

989 citations

20 papers · 724 indexed · h-index 13

Hepatology top 5%
Pharmacology top 10%
- Pharmacogenetics and Drug Metabolism 3
Oncology
- Drug Transport and Resistance Mechanisms 6
- Chemokine receptors and signaling 4
Epidemiology
- Liver Disease Diagnosis and Treatment 2
Pharmaceutical Science top 10%
Pulmonary and Respiratory Medicine
- Inhalation and Respiratory Drug Delivery 3
Immunology
- Immunotherapy and Immune Responses 3
- Immune Cell Function and Interaction 2
Pediatrics, Perinatology and Child Health
- Pharmacological Effects and Toxicity Studies 2

Co-authors: Ken Grime Charles D. Surh Ross L. Coppel Rolland E. Dickson Barry H. Hirst Douglas Ferguson Vanessa Moore Aftab A. Ansari
Cited by: Hepatology Pharmacology Oncology
Journals: Bioorganic & Medicinal Chemistry Letters (5 papers)Drug Metabolism and Disposition (3 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)
Partner nations: United Kingdom United States Sweden

In The Last Decade

Anne Cooper

20 papers receiving 704 citations

Peers

Countries citing papers authored by Anne Cooper

Since Specialization

Citations

This map shows the geographic impact of Anne Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Cooper more than expected).

Fields of papers citing papers by Anne Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Cooper. The network helps show where Anne Cooper may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Anne Cooper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anne Cooper Line = papers co-authored together Anne Cooper links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies Journal of Pharmacology and Experimental Therapeutics ·K.A. Bennett,Eugenia Sergeev,Cliona MacSweeney,Geor Bakker,Anne Cooper	2021	3
2	Digoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein/MDR1 European Journal of Pharmaceutics and Biopharmaceutics ·Victoria Hutter,David Chau,Constanze Hilgendorf,Alan Brown,Anne Cooper,Zhigang Zhang,David Pritchard,Cynthia Bosquillon	2013	10
3	A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder Translational Psychiatry ·Roscoe O. Brady,Anne Cooper,昌壽伊藤,Neeraj Tandon,Bruce M. Cohen,Perry F. Renshaw,Matcheri S. Keshavan,Döst Öngür	2012	33
4	Evaluation of layers of the rat airway epithelial cell line RL-65 for permeability screening of inhaled drug candidates European Journal of Pharmaceutical Sciences ·Victoria Hutter,Constanze Hilgendorf,Anne Cooper,Zhigang Zhang,David Pritchard,Cynthia Bosquillon	2012	3
5	Optimisation of DMPK by the Inhaled Route: Challenges and Approaches Current Drug Metabolism ·Anne Cooper,Douglas Ferguson,Ken Grime	2012	78
6	Unusual structure–genotoxicity relationship in mouse lymphoma cells observed with a series of kinase inhibitors Mutation Research/Genetic Toxicology and Environmental Mutagenesis ·Michael Fellows,Tim Luker,Anne Cooper,Michael R. O’Donovan	2012	5
7	Prediction of Efficacious Inhalation Lung Doses via the Use of In Silico Lung Retention Quantitative Structure-Activity Relationship Models and In Vitro Potency Screens Drug Metabolism and Disposition ·Anne Cooper,Tamara Ivancich,Tim Luker	2010	20
8	Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamides Bioorganic & Medicinal Chemistry Letters ·John G. Cumming,S Brown,Anne Cooper,Умида Баходировна Тухтаматова,Aaron Munn,Ken Grime,J.W. Oldfield,John S. Shaw,D.G. Cho,Howard Tucker,David Whittaker	2006	15
9	Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides Bioorganic & Medicinal Chemistry Letters ·John G. Cumming,Anne Cooper,Ken Grime,陈永顶,Syahrani Nurul Mutmainannah,J.W. Oldfield,John S. Shaw,Howard Tucker,Jon Winter,David Whittaker	2005	21
10	Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists Bioorganic & Medicinal Chemistry Letters ·Andrew Baxter,Anne Cooper,Henri Menjaud,Maheswara Rabbani,John Unitt,A.V. Wallace	2005	44
11	Differential Multidrug Resistance-Associated Protein 1 through 6 Isoform Expression and Function in Human Intestinal Epithelial Caco-2 Cells Journal of Pharmacology and Experimental Therapeutics ·U. Räse,L. Cardascia,Anne Cooper,Vanessa Moore,Barry H. Hirst	2004	116
12	P-glycoprotein Potentiates CYP3A4-mediated Drug Disappearance during Caco-2 Intestinal Secretory Detoxification Journal of drug targeting ·杜仲,Anne Cooper,Ileen Vira,Dianne Ford,Barry H. Hirst	2004	19
13	Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors Bioorganic & Medicinal Chemistry Letters ·Andrew Baxter,RM Fauzih,Anne Cooper,Eike Floettmann,Karen. Macaskill,Abdikarim Abdi Abdulle,Jason G. Kettle,Tom McInally,Craig A. Martin,Ebubekir Karabuğa,M. Needham,Pete Newham,Stuart W. Paine,Stephen A. St-Gallay,Didier Contardo,John Unitt,Yafeng Xue	2004	70
14	Hit-to-Lead studies: The discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists Bioorganic & Medicinal Chemistry Letters ·Andrew Baxter,L I Gustova,Fondo Editorial UNAMBA,Coignard J eacute r ocirc me,RM Fauzih,Anne Cooper,Henri Menjaud,Nicholas D. Kindon,Tom McInally,R. Sugumar,Bryan Roberts,John Unitt	2003	31
15	The Influence of DMPK as an Integrated Partner in Modern Drug Discovery Current Drug Metabolism ·Robert J. Riley,Iain Martin,Anne Cooper	2002	24
16	Excretion and metabolism of tipredane, a novel glucocorticoid, in the rat, mouse, monkey, and human. Drug Metabolism and Disposition ·Anne Cooper,Andrew Gray,陈邦柱,H. J. Seddon,Iain G. Beattie,C. J. Logan	1996	5
17	Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride. Drug Metabolism and Disposition ·Robert J. Riley,Craig Lambert,Anne Cooper,Lidija Kalinović,Michael Hall,S. Sylva,C. J. Logan,Beatrice Bin	1995	5
18	Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin‐converting enzyme, in the rat British Journal of Pharmacology ·Richard D. Carr,Anne Cooper,J. Kluthcouski,景丽英,Orchidamoty Orchidamoty,David Robinson,Keita HlRAI	1990	7
19	Detection of Autoantibodies to Recombinant Mitochondrial Proteins in Patients with Primary Biliary Cirrhosis New England Journal of Medicine ·Judy Van de Water,Anne Cooper,Charles D. Surh,Ross L. Coppel,Dean J. Danner,Aftab A. Ansari,Rolland E. Dickson,M. Eric Gershwin	1989	161
20	The predominance of IgG3 and IgM isotype antimitochondrial autoantibodies against recombinant fused mitochondrial polypeptide in patients with primary biliary cirrhosis Hepatology ·Charles D. Surh,Anne Cooper,Ross L. Coppel,Nathan J. Oborny,Aftab Ahmed,Rolland E. Dickson,Eric M. Gershwin	1988	54

About Anne Cooper

Anne Cooper is a scholar working on Oncology, Pharmacology, Hepatology, Immunology and Gastroenterology, having authored 20 papers that have together received 724 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (6 papers), Chemokine receptors and signaling (4 papers), Inhalation and Respiratory Drug Delivery (3 papers), Pharmacogenetics and Drug Metabolism (3 papers), Immunotherapy and Immune Responses (3 papers), Liver Disease Diagnosis and Treatment (2 papers), Immune Cell Function and Interaction (2 papers) and Pharmacological Effects and Toxicity Studies (2 papers). The work is most often cited by research in Hepatology (168 citations), Pharmacology (69 citations), Oncology (211 citations), Epidemiology (169 citations) and Pharmaceutical Science (29 citations). Anne Cooper has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Ken Grime, Charles D. Surh, Ross L. Coppel, Rolland E. Dickson, Barry H. Hirst, Douglas Ferguson, Vanessa Moore, Aftab A. Ansari, M. Eric Gershwin and Dean J. Danner. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, Current Drug Metabolism and European Journal of Pharmaceutical Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact